OBJECTIVES:   G-CSFs can decrease the incidence of febrile neutropenia (FN) among cancer patients receiving highly myelosuppressive chemotherapy regimens.  The primary objective of this pilot study was to determine the feasibility of a discrete choice survey on prophylactic G-CSF (pegfilgrastim and filgrastim) use in patients diagnosed with breast cancer as well as refine the survey instrument before proceeding with the full study population.  METHODS: A web-based discrete choice survey of patients diagnosed with breast cancer, and previously treated with chemotherapy, was conducted. The pilot survey was developed based on literature review, clinical consultation and 6 in-depth and 4 pre-test interviews with breast cancer patients. The experimental design was generated using Sawtooth software with 16 paired treatment-scenarios, comparing pegfilgrastim to filgrastim at 6- or 11-doses with a follow-up “no treatment” option. The 5 attributes included: frequency of treatment, inconvenience of treatment, risk of disruption to chemotherapy schedule due to low white blood cell counts, risk of developing an infection requiring hospitalization, and patient out-of-pocket cost. Demographics, clinical characteristics, healthcare costs and attitudinal data were also collected.  RESULTS: The responses from 29 of the thirty-two patients (91%) surveyed were analyzed. Most patients were able to answer questions regarding FN, including whether their healthcare provider had discussed, and if they had received, any FN prophylaxis (81% and 60%, respectively).  The attribute with the most impact on patient’s choices was “risk of developing an infection”; whereas “inconvenience of treatment” had the least impact and was likely confounded with “frequency of treatment.” The median completion time was 13 minutes. CONCLUSIONS: The pilot study results suggest that the survey is feasible in the breast cancer population. The only change to the survey instrument will be the removal of the attribute “inconvenience of treatment”; otherwise, the 16 treatment-scenario design, including the “no treatment” option, will be maintained.